Literature DB >> 11920742

MYCN expression in human rhabdomyosarcoma cell lines and tumour samples.

Luisa Toffolatti1, Emanuela Frascella, Vito Ninfo, Claudio Gambini, Marco Forni, Modesto Carli, Angelo Rosolen.   

Abstract

The MYCN oncogene encodes a phosphoprotein that acts as a transcription factor and is involved in the regulation of cell proliferation and differentiation in normal as well as in cancer cells.MYCN amplification and expression have been reported in various tumours, including neuroblastoma and lung cancer, but little is known about its expression in human rhabdomyosarcoma. MYCN expression and amplification were studied in five alveolar and five embryonal rhabdomyosarcoma cell lines and in 19 tumour biopsies. All the cell lines studied expressed MYCN RNA, as demonstrated by northern blot analysis and RT-PCR, but the oncogene was amplified in only one. Similarly, MYCN protein was detected in all cell lines by western blot analysis, with higher levels of expression in alveolar than in embryonal rhabdomyosarcoma cells. RT-PCR analysis of tumour samples demonstrated 18/19 cases positive for MYCN RNA. Although MYCN expression was higher in alveolar than in embryonal rhabdomyosarcoma cell lines, no clear relationship between histology and level of MYCN expression could be established in this tumour series. These data suggest that MYCN expression is a common feature of rhabdomyosarcoma, independent of gene amplification and without a clear relationship with specific histological and clinical features. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920742     DOI: 10.1002/path.1068

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  10 in total

1.  Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression.

Authors:  Beverly A Teicher; Eric Polley; Mark Kunkel; David Evans; Thomas Silvers; Rene Delosh; Julie Laudeman; Chad Ogle; Russell Reinhart; Michael Selby; John Connelly; Erik Harris; Anne Monks; Joel Morris
Journal:  Mol Cancer Ther       Date:  2015-09-08       Impact factor: 6.261

2.  Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors.

Authors:  Myriam Goldstein; Isaac Meller; Josephine Issakov; Avi Orr-Urtreger
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

3.  The mTOR pathway negatively controls ATM by up-regulating miRNAs.

Authors:  Changxian Shen; Peter J Houghton
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 11.205

4.  Sulforaphane induces apoptosis in rhabdomyosarcoma and restores TRAIL-sensitivity in the aggressive alveolar subtype leading to tumor elimination in mice.

Authors:  Elisa Bergantin; Carmelo Quarta; Cristina Nanni; Stefano Fanti; Andrea Pession; Giorgio Cantelli-Forti; Roberto Tonelli; Patrizia Hrelia
Journal:  Cancer Biol Ther       Date:  2014-06-27       Impact factor: 4.742

5.  Differential cooperation of oncogenes with p53 and Bax to induce apoptosis in rhabdomyosarcoma.

Authors:  Alan C Taylor; Katja Schuster; Pamela P McKenzie; Linda C Harris
Journal:  Mol Cancer       Date:  2006-11-02       Impact factor: 27.401

6.  Reductions in expression of growth regulating genes in skeletal muscle with age in wild type and myostatin null mice.

Authors:  Jennifer C Jones; Kellie A Kroscher; Anna C Dilger
Journal:  BMC Physiol       Date:  2014-03-28

Review 7.  The MYCN Protein in Health and Disease.

Authors:  María Victoria Ruiz-Pérez; Aine Brigette Henley; Marie Arsenian-Henriksson
Journal:  Genes (Basel)       Date:  2017-03-30       Impact factor: 4.096

8.  Bromodomain Inhibitor JQ1 Provides Novel Insights and Perspectives in Rhabdomyosarcoma Treatment.

Authors:  Irene Marchesi; Milena Fais; Francesco Paolo Fiorentino; Valentina Bordoni; Luca Sanna; Stefano Zoroddu; Luigi Bagella
Journal:  Int J Mol Sci       Date:  2022-03-25       Impact factor: 5.923

9.  Alveolar rhabdomyosarcoma - The molecular drivers of PAX3/7-FOXO1-induced tumorigenesis.

Authors:  Amy D Marshall; Gerard C Grosveld
Journal:  Skelet Muscle       Date:  2012-12-03       Impact factor: 4.912

10.  MicroRNA-27a Contributes to Rhabdomyosarcoma Cell Proliferation by Suppressing RARA and RXRA.

Authors:  Lucia Tombolan; Matteo Zampini; Silvia Casara; Elena Boldrin; Angelica Zin; Gianni Bisogno; Angelo Rosolen; Cristiano De Pittà; Gerolamo Lanfranchi
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.